Price movement over the last 24 hours
Accenture plc vs 22nd Century Group Inc — how do they compare? Accenture plc trades at $137.69 (market cap $86.98B), while 22nd Century Group Inc trades at $4.16 (market cap $1.48M). The key difference: Accenture plc is far larger — about 58770.3× 22nd Century Group Inc's market cap, and Accenture plc pays a 4.59% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| ACN | XXII | |
|---|---|---|
Market Cap | $86.98B | $1.48M |
Sector | Technology | Technology |
52-Week High | $303.33 | $2.04K |
52-Week Low | $124.41 | $3.90 |
Enterprise Value | $85.20B | -$6.75M |
Dividend Yield | 4.59% | — |
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $137.19, up 0.17% on the day, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 11.35, net income margin of 10.66%, and consistent earnings beats in recent quarters. Recent news highlights strategic AI partnerships with TEPCO Solution Advance and AlphaSense, reinforcing its focus on digital transformation services. Operating cash flow strengthened to $11.47 billion in 2025, supporting dividend payments and growth initiatives.
The outlook for ACN is positive, driven by strong analyst sentiment with a consensus price target of $193.92 and 66% buy ratings. Key opportunities include revenue growth from AI adoption and global consulting demand. Risks involve competitive pressures, macroeconomic sensitivity, and execution challenges in integrating new technologies. The stock offers value with reasonable valuation multiples and a track record of profitability.
XXII trades at $4.28, up 6.73% in the last session, amid a bearish technical outlook. The company reported a net loss of $5.05M on $7.05M revenue in 2025, with negative profitability margins. Recent news highlights expansion of its VLN reduced-nicotine cigarettes into California and New York, aiming to capture market share. A 20:1 reverse stock split was executed on June 12, 2026, to adjust the share structure.
The outlook remains speculative with high execution risk; analyst consensus is 75% buy but fundamentals show deep losses. Key risks include sustained negative cash flow, regulatory hurdles for tobacco products, and reliance on financing. Upside depends on successful commercialization of VLN products and achieving profitability.
Trailing returns across standard periods
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →